Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Molecular Blood Test Detects Colorectal Cancer

By Labmedica International staff writers
Posted on 26 Feb 2013
A molecular blood test that identifies changes in DNA associated with colorectal cancer is now available in the United States.

The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths, but only 40% of cases are diagnosed in early stages, due to low screening rates.

The new test is based on DNA methylation of the Septin9 gene, a proprietary biomarker associated with colorectal cancer that was identified by Epigenomics AG (Frankfurt, Germany). Epigenomics has demonstrated in more than a half dozen peer-reviewed studies involving approximately 3,000 specimens of patients with diagnosed colorectal cancer and of healthy control subjects that methylated Septin9 in blood plasma indicates an increased likelihood of colorectal cancer.

Epigenomics is sponsoring a multicenter clinical study named PRESEPT in collaboration with Quest Diagnostics (Madison, NJ, USA) and other organizations to evaluate the Septin9 biomarker's performance for colorectal cancer screening in screening-guideline-eligible individuals who have not been diagnosed with colorectal cancer. Quest Diagnostics is the first commercial laboratory in the USA to offer a laboratory-developed test based on the Septin9 biomarker.

Jon R. Cohen, MD senior vice president and chief medical officer of Quest Diagnostics said, "Early detection rates are dismally low, largely because many patients find existing tests and procedures invasive or unpleasant. Our ColoVantage colorectal cancer test, which is based on Septin9, has yet to be clinically validated as a screening test. Rather, it may promote further evaluation in patients who have resisted testing in the past or as an adjunct to existing procedures." ColoVantage was validated in multiple studies and achieved an overall 70% sensitivity and 89% specificity. ColoVantage has successfully detected cancer at all stages. Patients who test positive for methylated Septin9 should be further evaluated for the presence of colorectal cancer.

Related Links:
Epigenomics AG
Quest Diagnostics


77 ELEKTRONIKA
KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS

Channels

Genetic Tests

view channel
Image: Globoid cell leukodystrophy: Mulinucleated macrophages (\"globoid cells\") and loss of myelinated fibers in a case of Krabbe\'s leukodystrophy (Photo courtesy of Wikimedia Commons).

Advanced Next-Generation Sequencing Assay Kit Now Available for the Diagnosis of Leukodystrophy

An advanced next-generation sequencing (NGS) assay kit is now available to augment the use of MRI scans to diagnose the class of brain disorders known as leukodystrophies. Leukodystrophies are genetic... Read more

Hematology

view channel
Image: The ADVIA 2120 Hematology System (Photo courtesy of Siemens).

Preoperative Blood Cell Ratios Predict Endometrial Cancer Survival

The variations in systemic inflammatory response biomarker levels have been associated with adverse clinical outcome in various malignancies and the host response to malignant tumors is characterized by... Read more

Immunology

view channel
Image: Long-lived plasma cells have a distinctive \"fried egg\" appearance, containing bubble-like vacuoles or lipid droplets, which are generally rare in bone marrow cell samples (Photo courtesy of Emory University).

Long-Lived Antibody-Producing Cells Identified in Bone Marrow

A distinct set of long-lived antibody-producing cells have been identified in the human bone marrow that function as an immune archive. These cells keep a catalog of how an adult's immune system responded... Read more

Lab Tech.

view channel
Image: Verigene System instrumentation consists of a Verigene Reader and one or multiple Verigene Processor SPs (Photo courtesy of Nanosphere).

Directed Molecular Diagnostic Tests Highlight Recent Microbiology Conference

The performance of a series of directed molecular diagnostic tests was confirmed by several studies presented at a recent microbiology conference. Nanosphere (Northbrook, IL, USA) manufactures tests... Read more

Industry News

view channel

Cancer Genetics Expands Access to Proprietary Diagnostics Through Agreement with Harvard Pilgrim

Under the terms of a new agreement between Cancer Genetics, Inc. (CGI; Morrisville, NC, USA) and Harvard Pilgrim Healthcare (Hartford, CT; USA), a health care network covering over one million people throughout Massachusetts, Connecticut, and Maine, CGI will offer its cancer diagnostic services to individuals covered under... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.